

RECEIVED
CENTRAL FAX CENTER

703-757-0956

P. 1

WILMER CUTLER PICKERING
HALE AND DORR *llw*

AUG 18 2004

FACSIMILE

OFFICIAL

DATE

August 18, 2004

TO

F. Pierre VanderVegt
U.S. Patent and Trademark Office

FAX

fax: 703-872-9306
phone: 571-272-0852

FROM

Maria L. Maebius
202-942-8452


NUMBER OF PAGES, INCLUDING COVER

18

THE WILLARD OFFICE BUILDING
1455 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, DC 20004
+1 202 942 8400
+1 202 942 8484 fax
wilmerhale.com

MESSAGE

I hereby acknowledge that I am transmitting by facsimile the enclosed Response under 37 CFR 1.111 and Exhibit on August 18, 2004.


Maria L. Maebius

This facsimile transmission is confidential and may be privileged. If you are not the intended recipient, please immediately call the sender or, if the sender is not available, call +1 202-942-8333 and destroy all copies of this transmission. If the transmission is incomplete or illegible, please call the sender or, if the sender is not available, call +1 202-942-8333. Thank you.

BALTIMORE BERLIN BOSTON BRUSSELS LONDON MUNICH
NEW YORK NORTHERN VIRGINIA OXFORD PRINCETON WALTHAM WASHINGTON

AUG 18 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

D. Clark Bennett et al.

Serial No.: 08/722,659

Filed: 27 September 1996

FOR: USE OF HEPARINASE TO
DECREASE INFLAMMATORY
RESPONSE

Group Art Unit: 1644

Examiner: P. VanderVegt

Atty. Dkt. No. 104385.140

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**RESPONSE UNDER 37 CFR 1.111**

This response is submitted in response to the Office Action dated May 18, 2004, for which a response is due by August 18, 2004. No fees are believed due; however, the Commissioner is authorized to charge any additional fees which may be due, or credit any overpayment, to Deposit Account 08-0219, to maintain the pendency of the present application.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.